185 related articles for article (PubMed ID: 33592266)
21. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
Neha ; Das P; Verma SP
Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
[TBL] [Abstract][Full Text] [Related]
22. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma.
Clark J; Lu YJ; Sidhar SK; Parker C; Gill S; Smedley D; Hamoudi R; Linehan WM; Shipley J; Cooper CS
Oncogene; 1997 Oct; 15(18):2233-9. PubMed ID: 9393982
[TBL] [Abstract][Full Text] [Related]
23. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
24. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
25. TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.
Damayanti NP; Cordova RA; Rupert C; Delle Fontane I; Shen L; Orsi S; Klunk AJ; Linehan WM; Staschke KA; Hollenhorst PC; Heppner DE; Pili R
Cancer Res; 2024 Apr; 84(8):1286-1302. PubMed ID: 38266162
[TBL] [Abstract][Full Text] [Related]
26. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
28. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis.
Prakasam G; Mishra A; Christie A; Miyata J; Carrillo D; Tcheuyap VT; Ye H; Do QN; Wang Y; Reig Torras O; Butti R; Zhong H; Gagan J; Jones KB; Carroll TJ; Modrusan Z; Durinck S; Requena-Komuro MC; Williams NS; Pedrosa I; Wang T; Rakheja D; Kapur P; Brugarolas J
J Clin Invest; 2024 Feb; 134(7):. PubMed ID: 38386415
[TBL] [Abstract][Full Text] [Related]
29. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.
Argani P; Lal P; Hutchinson B; Lui MY; Reuter VE; Ladanyi M
Am J Surg Pathol; 2003 Jun; 27(6):750-61. PubMed ID: 12766578
[TBL] [Abstract][Full Text] [Related]
30. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
31. Molecular heterogeneity of TFE3 activation in renal cell carcinomas.
Macher-Goeppinger S; Roth W; Wagener N; Hohenfellner M; Penzel R; Haferkamp A; Schirmacher P; Aulmann S
Mod Pathol; 2012 Feb; 25(2):308-15. PubMed ID: 22037260
[TBL] [Abstract][Full Text] [Related]
32. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect.
Kuroda N; Mikami S; Pan CC; Cohen RJ; Hes O; Michal M; Nagashima Y; Tanaka Y; Inoue K; Shuin T; Lee GH
Histol Histopathol; 2012 Feb; 27(2):133-40. PubMed ID: 22207547
[TBL] [Abstract][Full Text] [Related]
33. Establishment of an ASPL-TFE3 renal cell carcinoma cell line (S-TFE).
Hirobe M; Masumori N; Tanaka T; Kitamura H; Tsukamoto T
Cancer Biol Ther; 2013 Jun; 14(6):502-10. PubMed ID: 23760492
[TBL] [Abstract][Full Text] [Related]
34. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
Classe M; Malouf GG; Su X; Yao H; Thompson EJ; Doss DJ; Grégoire V; Lenobin J; Fantoni JC; Sudour-Bonnange H; Khayat D; Aubert S; Tannir NM; Leroy X
Histopathology; 2017 Jun; 70(7):1089-1097. PubMed ID: 28106924
[TBL] [Abstract][Full Text] [Related]
35. [The translocation carcinoma: A pediatric renal tumor also in adults].
Bruder E; Moch H
Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
[TBL] [Abstract][Full Text] [Related]
36. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.
Tsuda M; Davis IJ; Argani P; Shukla N; McGill GG; Nagai M; Saito T; Laé M; Fisher DE; Ladanyi M
Cancer Res; 2007 Feb; 67(3):919-29. PubMed ID: 17283122
[TBL] [Abstract][Full Text] [Related]
37. NONO::TFE3 fusion cutaneous epithelioid and spindle cell tumor: A case series.
See SHC; Olivares S; Kulkarni M; Dhillon SK; Fumero-Velazquez MS; Hagstrom MNE; Gerami P
J Cutan Pathol; 2023 Nov; 50(11):956-962. PubMed ID: 37606377
[TBL] [Abstract][Full Text] [Related]
38. A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
Ye H; Qin S; Li N; Lin M; Xu Y; Li X
Biomed Res Int; 2019; 2019():5974089. PubMed ID: 31828108
[TBL] [Abstract][Full Text] [Related]
39. Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum.
Wang XT; Xia QY; Ni H; Wang ZY; Ye SB; Li R; Wang X; Lv JH; Shi SS; Ma HH; Lu ZF; Shen Q; Zhou XJ; Rao Q
Histopathology; 2016 Sep; 69(3):450-8. PubMed ID: 26844676
[TBL] [Abstract][Full Text] [Related]
40. PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.
Xiong L; Chen X; Liu N; Wang Z; Miao B; Gan W; Li D; Guo H
PLoS One; 2017; 12(9):e0185337. PubMed ID: 28949976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
